Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell 5Arthritis, Rheumatoid 5Solid Tumors 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Colorectal Neoplasms 3Ovarian Neoplasms 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Spondylitis, Ankylosing 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Esophageal Neoplasms 1

Interventions

pembrolizumab 15Pemetrexed 15Cisplatin 12Nivolumab 9Carboplatin 8Ipilimumab 7tazemetostat 3fludarabine 3anetumab ravtansine 3Cyclophosphamide 3spartalizumab 2budigalimab 2belinostat 2atezolizumab 2amatuximab 2Vinorelbine 2Paclitaxel 2Gemcitabine 2Docetaxel 2venetoclax 1vandetanib 1trametinib 1tocilizumab 1tislelizumab 1sotorasib 1ruxolitinib 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma × tocilizumab × Clear all
NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Terminated
61 enrolled 29 charts
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡